Login to Your Account



With Pier Buy, Cortex to Focus on Sleeping Disorders

By Marie Powers
Staff Writer

Wednesday, August 15, 2012
Cortex Pharmaceuticals Inc. and privately held Pier Pharmaceuticals Inc. completed an all-stock merger, adding a Phase II-ready obstructive sleep apnea compound to a pipeline now focused exclusively on brain-controlled sleeping disorders. Rebranding Cortex in the sleep apnea market, which has no pharmaceutical options, could create a biotech with greater value than the sum of its parts.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription